Ocugen, Inc. — Director's Dealing 2015

Jul 31, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2015-07-29

Reporting Person: Kennedy Stephen Richard (Chief Technology Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-07-29	Employee Stock Option (Right to Buy)	$6.11	A	50000	Acquired	2025-07-29	Common Stock (50000)	Direct

Footnotes

F1: This option vests over four (4) years of continuous service following July 29, 2015, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and the balance vesting in thirty-six (36) equal monthly installments thereafter.